Following the completion of the Genentech transaction, Roche has made organizational structure changes and filled key management positions that will become effective May 1, 2009.

Arthur D. Levinson, currently Genentech’s chairman and chief executive officer, will chair Genentech’s new board of directors and head the integration of the two companies on a strategic level. Mr. Levinson will also serve as an advisor to Genentech’s Research and Early Development center, and will join the Scientific Resource Board (SRB), its external advisory group.

Susan Desmond-Hellmann, currently president Genentech product development, will continue to support the integration planning and her current responsibilities until mid year. She will then contribute to Genentech in an advisory role. She will also join the Genentech SRB.

Genentech’s Research and Early Development will operate as an independent center within the Roche Group. Richard Scheller, currently executive vice president Genentech Research, will lead this center and report to group chief executive officer Severin Schwan. Richard Scheller is appointed to the enlarged Roche corporate executive committee, effective immediately.

Marc Tessier-Lavigne, currently executive vice president Genentech Research Drug Discovery, will continue to report to Mr. Scheller and succeed him as executive vice president research. Mr. Tessier-Lavigne is appointed as Genentech’s chief scientific officer.

Pascal Soriot will be appointed as chief executive officer of Genentech. He will lead all pharma activities in the U.S. and report directly to Mr. Schwan. Mr. Soriot has also been appointed as a member of the corporate executive committee, effective immediately. For an interim period, this function will also be led directly by William M. Burns, chief executive officer Roche Pharmaceuticals. Mr. Soriot will directly lead the combined commercial operations of Roche Pharma North America and Genentech, headquartered in South San Francisco.

George Abercrombie, chief executive officer and president of Hoffmann-La Roche, has agreed to support the integration through the end of 2009. In this role he will assist Mr. Soriot with the transition of the U.S. commercial headquarters from Nutley to South San Francisco. A site head for the R&D center in Nutley will be announced at a later date.

David A. Ebersman, currently executive vice president and chief financial officer, and Steve Juelsgaard, executive vice president Genentech secretary and chief compliance officer, will be leaving Genentech. Their responsibilities will be organized as follows:

Steve Krognes, currently head of Roche Corporate Business Development, will be appointed as chief financial officer Genentech and senior vice president regional head finance and IT Pharma North America. Rick Kentz, currently vice president secretary and legal affairs Roche Pharma North America, will be appointed senior vice president, secretary and chief compliance officer, for the combined organization with responsibilities for legal and corporate services. Steve Grossmann, currently vice president human resources Roche Pharma North America, will be appointed as senior vice president regional head human resources Pharma North America for the combined organization. Denise Smith-Hams, currently vice president Genentech human resources, will be promoted to senior vice president Genentech human resources. Christine Castro, vice president corporate relations Genentech, will be appointed senior vice president regional head public relations Pharma North America. She will be based in South San Francisco and report to Mr. Soriot.

Ian Clark, currently executive vice president, commercial operations, Genentech, will take over responsibility as executive vice president global marketing and chief marketing officer of the Roche Pharma division. He will be located in South San Francisco and report to Mr. Soriot.

Pat Yang will continue as executive vice president technical operations Genentech and report functionally to Jan van Koeveringe, head global technical operations Pharma, and locally to Mr. Soriot.

Hal Barron, currently senior vice president Genentech development and chief medical officer, will be appointed executive vice president and head of global development responsible for early and late development for oncology, immunology/tissue growth repair, and virology. He will be based in South San Francisco and will report functionally to Jean-Jacques Garaud, head of global development Roche Pharma, and locally to Mr. Soriot. He will also be appointed as chief medical officer for the combined U.S. organization.

Mr. Levinson and Mr. Soriot will lead the operational integration team to design the future set-up of the combined company. The integration plans will be finalized by mid-year with the goal of completion by the end of this year. Following the integration, Mr. Soriot will resume his current responsibilities as head of Global Pharma commercial operations as a member of the corporate executive committee.

William M. Burns, chief executive officer, Roche Pharma, will retire from the corporate executive committee, effective January 1, 2010. His successor will be announced at a later date.

“Roche and Genentech have always shared a focus on scientific discovery and a commitment to achieving medical breakthroughs that can enhance and even save lives. The companies’ efficient and strategic integration of its personnel and operations reflects these shared values, and I am confident that our combined organization will be even more capable of delivering significant achievements,” said Mr. Levinson. “All of what Genentech has achieved during its 33-year history is due to the extraordinary talents and efforts of individuals who have dedicated themselves wholly to our mission. Among those individuals whose contributions to the company are difficult to overstate are Sue Desmond-Hellmann, Steve Juelsgaard and David Ebersman. Genentech simply would not be the success it is today without them and on behalf of all Genentech employees I want to offer them my deepest thanks.”

Mr. Schwan commented, “I am extremely grateful to George Abercrombie for his many valuable contributions to Roche and for his support in transitioning to the new organization. We are also delighted that many outstanding individuals from both Genentech and Roche have committed themselves to driving forward the combined businesses. We look forward to maintaining the excellent momentum of the integration.”